The Potential of Repurposed Drugs Targeting COVID-19: The COLCORONA Study Results Published in The Lancet Reveal Promise with Colchicine

The Potential of Repurposed Drugs Targeting COVID-19 The COLCORONA Study Results Published in The Lancet Reveal Promise with Colchicine

Back on January 23, 2021, TrialSite reported that the Montreal Heart Institute’s COLCOONA trial’s results showed promise. The study involving 4,488 COVID-19 patients was associated with statistically significant reductions in the risk of death or hospitalization as compared to placebo. The gout drug colchicine actually reduced hospitalizations, the need for mechanical ventilation, and deaths due to COVID-19. These findings, suggested its authors, possibly introduced the first oral drug that could be used to treat non-hospitalized patients with COVID-19. However, those findings only applied to those actually diagnosed with PCR-confirmed COVID-19 and had not yet been peer-reviewed nor published. That status has most certainly changed as the prestigious journal The Lancet recently showcased COLCORONA and thus, reminds all of the importance of the potential of repurposed, generic, drugs as a potential tool in the war against COVID-19.

Early on, the researchers involved with this study undertook extensive searches to find anti-inflammatory agents that could be used against SRS-CoV-2, the virus behind COVID-19, which turned up the anti-inflammatory agent colchicin...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee